Inclusion complexes of atorvastatin calcium–sulfobutyl ether β cyclodextrin with enhanced hypolipidemic activity

Simple item page
dc.contributor.authorArora, Anureeten_US
dc.contributor.authorAggarwal, Geetaen_US
dc.contributor.authorSingh, Thakur Gurjeeten_US
dc.contributor.authorSingh, Manjinderen_US
dc.contributor.authorArora, Gitikaen_US
dc.contributor.authorNagpal, Manjuen_US
dc.date.accessioned2020-10-16T08:55:47Z
dc.date.available2020-10-16T08:55:47Z
dc.date.issued2019-11
dc.description.abstractThe aim of present study was to explore the impact of Atorvastatin (ATR) Sulfobutylether beta-cyclodextrin complex(ATR-SBE-β-CD) on ATR dissolution behavior. Various batches of inclusion complexes were formulated usingvarious drug: polymer ratios (1:1, 1:3, and 1:5); using β-CD and SBE-β-CD and using two methods (freeze dryingand kneading method). Phase solubility studies were carried out of all the complexes and ratio 1:5 (ATR-SBE-β-CD)prepared by freeze-drying yield maximum solubility enhancement (30-fold in comparison to pure drug). Fouriertransformation infrared spectroscopy, Powder X-ray diffraction, Scanning electron microscopy (SEM), Differentialscanning calorimetry (DSC) studies was also carried out. FTIR studies showed no drug polymer interaction. DSCand SEM studies suggested incorporation of drug into inclusion complexes of cyclodextrin. Solid dispersion viaFreeze drying technique using SBE-β-CD (1:3 ratio of drug to polymer) produces better dissolution characteristics incomparison to kneading method. The results revealed superiority of SBE-β-CD over β-CD for solubility enhancementof poorly soluble drugs (owing to amorphous nature and more stable form of SBE β-CD). No significant drug losswas observed in solid dispersion batch (as per results of drug content analysis) during storage for 3 months underaccelerated conditions. Further in vivo pharmacodynamics studies of selected batch were carried out by inducingobesity in rats by feeding them with a high-fat diet. Group I (normal control group) received normal chow diet andgroup II, group III, group IV (High fat diet group, optimized formulation group and disease control group) receivedHFD for 1 month and were further evaluated for BMI, Blood glucose, lipid profile, liver profile, and histopathologicalexamination. The results so obtained depicted that optimized formulation of Atorvastatin (10 mg/kg, p.o.) showedbetter results in comparison to pure Atorvastatin Calcium (10 mg/kg, p.o.).en_US
dc.identifier.affiliationsChitkara College of Pharmacy, Chitkara University, Punjab, Indiaen_US
dc.identifier.affiliationsDelhi Pharmaceutical Sciences and Research University, Govt. of NCT of Delhi, New Delhi, India.en_US
dc.identifier.affiliationsChitkara College of Pharmacy, Chitkara University, Punjab, Indiaen_US
dc.identifier.affiliationsChitkara College of Pharmacy, Chitkara University, Punjab, Indiaen_US
dc.identifier.affiliationsNCRDs Sterling Institute of Pharmacy, Navi Mumbai, Indiaen_US
dc.identifier.affiliationsChitkara College of Pharmacy, Chitkara University, Punjab, Indiaen_US
dc.identifier.citationArora Anureet, Aggarwal Geeta, Singh Thakur Gurjeet, Singh Manjinder, Arora Gitika, Nagpal Manju. Inclusion complexes of atorvastatin calcium–sulfobutyl ether β cyclodextrin with enhanced hypolipidemic activity. Journal of Applied Pharmaceutical Science. 2019 Nov; 2019 Nov: 060-068en_US
dc.identifier.issn2231-3354
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/210483
dc.languageenen_US
dc.publisherOpen Science Publishers LLPen_US
dc.relation.issuenumber11en_US
dc.relation.volume9en_US
dc.source.urihttps://dx.doi.org//10.7324/JAPS.2019.91108en_US
dc.subjectCyclodextrinsen_US
dc.subjectsolubilityen_US
dc.subjectdissolutionen_US
dc.subjecthistopathologyen_US
dc.subjectstabilityen_US
dc.subjectobesityen_US
dc.titleInclusion complexes of atorvastatin calcium–sulfobutyl ether β cyclodextrin with enhanced hypolipidemic activityen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
japs2019v9n11p060.pdf
Size:
3.54 MB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Applied Pharmaceutical Science (JAPS)